Gadolinium News and Research

RSS

Intracoronary and IV abciximab during angioplasty do not result in differences in myocardial damage

A study confirmed no differences in various measures of heart damage, according to cardiac magnetic resonance (MRI) imaging, in patients receiving the anti-clotting medication abxicimab directly into the heart (intracoronary) compared to those receiving it intravenously (IV).

26 Oct 2012

Jefferson researchers to investigate mechanisms involved in nephrogenic systemic fibrosis

Researchers at the Jefferson Institute of Molecular Medicine were awarded almost $384,000 by the National Institutes of Health to investigate the mechanisms involved in the development of a serious and sometimes fatal disease, known as Nephrogenic Systemic Fibrosis, a rare skin disorder linked to Gadolinium-based contrast agents used in magnetic resonance (MRI and MRA) studies.

26 Oct 2012

Biogen Idec announces new data from BG-12 Phase 3 studies on RRMS

Today Biogen Idec announced new data from studies evaluating oral BG-12 (dimethyl fumarate), which provide further evidence supporting its strong clinical and radiological effects in people with relapsing-remitting multiple sclerosis (RRMS) and reinforce its favorable safety profile seen to date.

12 Oct 2012

Fertility treatment may increase MS disease activity

Findings published in Annals of Neurology suggest that assisted reproduction technology treatment increases multiple sclerosis disease activity.

8 Oct 2012

Close monitoring could give early warning of MS disease course

Patients with multiple sclerosis who have breakthrough disease activity early in the course of treatment with interferon beta-1a are at high risk for severe worsening and poor long-term outcomes, research shows.

20 Sep 2012

New noninvasive imaging technique may help detect heart transplant rejection in children

Cardiologists at Washington University School of Medicine in St. Louis have developed a noninvasive imaging technique that may help determine whether children who have had heart transplants are showing early signs of rejection. The technique could reduce the need for these patients to undergo invasive imaging tests every one to two years.

14 Jul 2012

Neuroprotective effects underpin fingolimod benefits in MS

Fingolimod therapy reduces inflammatory activity and tissue loss in the brains of patients with multiple sclerosis, shows further analysis of the FREEDOMS trial.

10 Jul 2012

First clinical trial to test cardiac drug regimen for DMD

The first landmark randomized clinical trial for a cardiac drug regimen in Duchenne muscular dystrophy (DMD) is testing whether earlier treatment can stop or slow down heart damage that usually kills people with the disease.

27 Jun 2012

Evidence mounts for vitamin D multiple sclerosis role

Three studies published in Neurology add weight to the theory that vitamin D levels have an important effect on relapse rates and cerebral lesions in patients with multiple sclerosis.

20 Jun 2012

Spectrum initiates ZEVALIN and MGd Phase 2 combination study in NHL

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the initiation of a Phase 2 study evaluating ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use + rituximab in combination with motexafin gadolinium (MGd) in patients with rituximab-refractory low-grade or follicular B-cell non-Hodgkin's lymphoma.

18 May 2012

New technique could help improve prognosis of patients with brain cancers

Like special-forces troops laser-tagging targets for a bomber pilot, tiny particles that can be imaged three different ways at once have enabled Stanford University School of Medicine scientists to remove brain tumors from mice with unprecedented accuracy.

16 Apr 2012

Thermo Fisher Scientific introduces new ICP-MS system, iCAP Q

Thermo Fisher Scientific Inc., the world leader in serving science, today launched its new Thermo Scientific iCAP Q, an ICP-MS system that features world-class performance and increased throughput to help laboratories cut analysis times by up to 50 percent when compared to the XSERIES 2 ICP-MS, the model it replaces.

From Thermo Fisher Scientific Inc. 12 Mar 2012

Glycol chitosan-coated MRI agent safer, more effective in detecting breast cancer

Many imaging technologies and their contrast agents - chemicals used during scans to help detect tumors and other problems - involve exposure to radiation or heavy metals, which present potential health risks to patients and limit the ways they can be applied.

26 Dec 2011

Luminescent upconversion nanocrystals can detect cancer cells

Upconversion emission materials are ideal for bioimaging due to its effectiveness as contrast agents for the detection of cancer cells, more so when the background emission of non-cancerous tissues can be minimised. These materials could be used as biomarkers for luminescent labeling of cancerous cells. Opaque tissues can be turned into glassy, transparent substances by using these biomarkers which rely on near-infrared excitation.

14 Nov 2011

Role of cardiovascular magnetic resonance in clinical cardiology

Cardiovascular Magnetic Resonance (CMR) has undergone substantial development and offers important advantages compared with other well-established imaging modalities.

3 Nov 2011

Abbott, Biogen Idec announce additional results from daclizumab HYP Phase 2b trial for RRMS

Today Biogen Idec and Abbott announced additional results from the SELECT Phase 2b trial, the first of two registrational studies designed to evaluate the investigational compound daclizumab high-yield process in people with relapsing-remitting multiple sclerosis.

22 Oct 2011

New improved method can help doctors diagnose early-stage osteoarthritis

A new method is set to help doctors diagnose osteoarthritis at such an early stage that it will be possible to delay the progression of the disease by many years, or maybe even stop it entirely.

12 Sep 2011

Metallofullerene platform holds promise for treatment of brain tumors

A single compound with dual function - the ability to deliver a diagnostic and therapeutic agent - may one day be used to enhance the diagnosis, imaging and treatment of brain tumors, according to findings from Virginia Commonwealth University and Virginia Tech.

5 Aug 2011

Metallofullerene-based nanoplatform shows promise against glioblastomas

Researchers from two universities have developed and tested a molecular platform that offers hope for treatment of aggressive brain tumors.

4 Aug 2011

New weapon in the fight against cancer

A cancer diagnosis is not necessarily a death sentence. There are now quite a number of possibilities to treat cancer. In addition to radiotherapy and chemotherapy, so-called radionuclide treatment has also become an important component in the fight against the mutated cells. It involves injecting radioactive elements, so-called nuclides, into the patient's circulatory system.

17 Jun 2011